Synlogic, Inc.

About Synlogic, Inc.

Synlogic Therapeutics is a biotechnology company pioneering transformative biotherapeutics for patients. They work at the intersection of biology and engineering, utilizing synthetic biology to design living therapeutics that address the underlying drivers of disease, aiming to transform treatment paradigms and improve patient health.

Products & Services

Synthetic Biotics:Novel biotherapeutics designed to address the underlying causes of disease, with the potential to transform treatment approaches.

Specialties

Synthetic Biology Living Therapeutics Biotherapeutics Design

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 21000000 MR: - FA: 21.0 Million FAN: 21000000	D: 2023-09-29 FD: 2023-09-29	1 investors

Underwritten Public Offering Latest

2023-09-29

$21.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

James Collins

Co-Founder, Termeer Professor of Medical Engineering & Science, MIT

T

Tim Lu

Co-Founder and Associate Professor

M

Mary Beth Dooley

PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

P

Peter Barrett, PhD

Chairman, Partner, Atlas Venture

J

James Flynn

Independent

E

Ed Mathers

Partner, New Enterprise Associates

View 9 more team members with Pro

Unlock Full Team Directory

Recent News

Synlogic, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised